Mesoblast Analyst Ratings
Mesoblast Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/04/2023 | -62.41% | Chardan Capital | $2 → $1.5 | Maintains | Sell |
| 05/30/2023 | -49.87% | Chardan Capital | $2.5 → $2 | Maintains | Sell |
| 03/01/2023 | -37.34% | Chardan Capital | → $2.5 | Reiterates | → Sell |
| 02/01/2023 | 476.44% | Cantor Fitzgerald | → $23 | Reiterates | → Overweight |
| 12/06/2022 | — | Jefferies | Downgrades | Buy → Hold | |
| 09/06/2022 | 75.44% | Piper Sandler | → $7 | Initiates Coverage On | → Overweight |
| 06/03/2022 | -37.34% | Chardan Capital | $6.5 → $2.5 | Maintains | Sell |
| 08/31/2021 | 62.91% | Chardan Capital | $7.5 → $6.5 | Maintains | Sell |
| 04/07/2021 | — | Maxim Group | Upgrades | Hold → Buy | |
| 01/19/2021 | — | Jefferies | Downgrades | Buy → Hold | |
| 12/22/2020 | — | Maxim Group | Downgrades | Buy → Hold | |
| 12/04/2020 | 87.97% | Chardan Capital | $5.5 → $7.5 | Downgrades | Neutral → Sell |
| 11/20/2020 | 401.25% | HC Wainwright & Co. | $19 → $20 | Maintains | Buy |
| 10/22/2020 | 200.75% | RBC Capital | → $12 | Initiates Coverage On | → Sector Perform |
| 10/02/2020 | 376.19% | HC Wainwright & Co. | $21 → $19 | Maintains | Buy |
| 05/28/2020 | 426.32% | HC Wainwright & Co. | $14 → $21 | Reiterates | → Buy |
| 10/22/2019 | 476.44% | Cantor Fitzgerald | → $23 | Assumes | → Overweight |
| 01/31/2019 | 62.91% | HC Wainwright & Co. | → $6.5 | Assumes | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/04/2023 | -62.41% | 查丹资本 | $2 → 1.5 美元 | 维护 | 卖出 |
| 05/30/2023 | -49.87% | 查丹资本 | 2.5 美元 → 2 美元 | 维护 | 卖出 |
| 03/01/2023 | -37.34% | 查丹资本 | → 2.5 美元 | 重申 | → 卖出 |
| 02/01/2023 | 476.44% | 坎托·菲茨杰拉德 | → 23 美元 | 重申 | → 超重 |
| 12/06/2022 | — | 杰富瑞 | 降级 | 买入 → 持有 | |
| 09/06/2022 | 75.44% | 派珀·桑德勒 | → 7 美元 | 启动覆盖开启 | → 超重 |
| 06/03/2022 | -37.34% | 查丹资本 | 6.5 美元 → 2.5 美元 | 维护 | 卖出 |
| 08/31/2021 | 62.91% | 查丹资本 | 7.5 美元 → 6.5 美元 | 维护 | 卖出 |
| 2021 年 7 月 4 日 | — | Maxim 集团 | 升级 | 持有 → 买入 | |
| 2021 年 1 月 19 日 | — | 杰富瑞 | 降级 | 买入 → 持有 | |
| 12/22/2020 | — | Maxim 集团 | 降级 | 买入 → 持有 | |
| 2020 年 4 月 12 日 | 87.97% | 查丹资本 | 5.5 美元 → 7.5 美元 | 降级 | 中性 → 卖出 |
| 11/20/2020 | 401.25% | HC Wainwright & Co. | 19 美元 → 20 美元 | 维护 | 购买 |
| 2020 年 10 月 22 日 | 200.75% | 加拿大皇家银行资本 | → 12 美元 | 启动覆盖开启 | → 行业表现 |
| 2020 年 2 月 10 日 | 376.19% | HC Wainwright & Co. | 21 美元 → 19 美元 | 维护 | 购买 |
| 05/28/2020 | 426.32% | HC Wainwright & Co. | 14 美元 → 21 美元 | 重申 | → 购买 |
| 2019 年 10 月 22 日 | 476.44% | 坎托·菲茨杰拉德 | → 23 美元 | 假设 | → 超重 |
| 01/31/2019 | 62.91% | HC Wainwright & Co. | → 6.5 美元 | 假设 | → 购买 |
What is the target price for Mesoblast (MESO)?
Mesoblast (MESO) 的目标价格是多少？
The latest price target for Mesoblast (NASDAQ: MESO) was reported by Chardan Capital on August 4, 2023. The analyst firm set a price target for $1.50 expecting MESO to fall to within 12 months (a possible -62.41% downside). 6 analyst firms have reported ratings in the last year.
Chardan Capital于2023年8月4日公布了Mesoblast（纳斯达克股票代码：MESO）的最新目标股价。这家分析公司将目标股价定为1.50美元，预计MESO将在12个月内跌至-62.41％（下跌幅度可能为-62.41％）。去年有6家分析公司公布了评级。
What is the most recent analyst rating for Mesoblast (MESO)?
分析师对Mesoblast（MESO）的最新评级是多少？
The latest analyst rating for Mesoblast (NASDAQ: MESO) was provided by Chardan Capital, and Mesoblast maintained their sell rating.
Mesoblast（纳斯达克股票代码：MESO）的最新分析师评级由Chardan Capital提供，Mesoblast维持其卖出评级。
When is the next analyst rating going to be posted or updated for Mesoblast (MESO)?
Mesoblast（MESO）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mesoblast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mesoblast was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Mesoblast的高管和客户交谈以及听取财报电话会议）后得出了股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Mesoblast的最后一次评级是在2023年8月4日提交的，因此您应该预计下一个评级将在2024年8月4日左右公布。
Is the Analyst Rating Mesoblast (MESO) correct?
分析师对 mesoblast (MESO) 的评级是否正确？
While ratings are subjective and will change, the latest Mesoblast (MESO) rating was a maintained with a price target of $2.00 to $1.50. The current price Mesoblast (MESO) is trading at is $3.99, which is out of the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的Mesoblast（MESO）评级维持不变，目标股价为2.00美元至1.50美元。Mesoblast（MESO）目前的交易价格为3.99美元，超出了分析师的预测区间。